Maravai Lifesciences Holdings (MRVI) Enterprise Value (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Enterprise Value of -$8.4 million for Q1 2026, up 84.83% year-over-year from -$4.5 million in Q1 2025, and up 85.14% quarter-over-quarter from -$56.6 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Enterprise Value (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Enterprise Value history runs 7 years deep, the most recent figure standing at -$8.4 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 84.83% year-over-year to -$8.4 million; the TTM figure through Mar 2026 stood at -$8.4 million (up 84.83% YoY), while the FY2025 annual figure was -$56.6 million, up 21.29% from the prior year.
- Enterprise Value for Q1 2026 stood at -$8.4 million, up from -$56.6 million in the prior quarter.
- The five-year high for Enterprise Value was $379.1 million in Q1 2023, with the low at -$310.4 million in Q3 2024.
- The 5-year median for Enterprise Value is -$67.8 million (2025), against an average of -$37.8 million.
- Peak annual rise in Enterprise Value reached 172.6% in 2022, while the deepest fall reached 218.38% in 2022.
- Maravai Lifesciences Holdings' Enterprise Value stood at -$272.1 million in 2022, then advanced by 25.83% to -$201.8 million in 2023, then surged by 64.4% to -$71.9 million in 2024, then gained by 21.29% to -$56.6 million in 2025, then soared by 85.14% to -$8.4 million in 2026.
- Business Quant data shows MRVI's Enterprise Value at -$8.4 million in Q1 2026, -$56.6 million in Q4 2025, and -$57.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 80.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.88 Mn |
| Mar 31, 2026 | -8.40 Mn |
| Dec 31, 2025 | -56.56 Mn |
| Sep 30, 2025 | -57.16 Mn |
| Jun 30, 2025 | -67.78 Mn |
| Mar 31, 2025 | -55.39 Mn |
| Dec 31, 2024 | -71.86 Mn |
| Sep 30, 2024 | -310.36 Mn |
| Jun 30, 2024 | -241.99 Mn |
| Mar 31, 2024 | -194.96 Mn |
| Dec 31, 2023 | -201.83 Mn |
| Sep 30, 2023 | -206.62 Mn |
| Jun 30, 2023 | -203.11 Mn |
| Mar 31, 2023 | 379.12 Mn |
| Dec 31, 2022 | -272.11 Mn |
| Sep 30, 2022 | 337.91 Mn |
| Jun 30, 2022 | 317.20 Mn |
| Mar 31, 2022 | 271.74 Mn |
| Dec 31, 2021 | 229.86 Mn |
| Sep 30, 2021 | 152.80 Mn |